Should I buy or sell Achilles Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Achilles Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ACHL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACHL, but not buy additional shares or sell existing shares. View ACHL analyst ratings or view top-rated stocks .

What is Achilles Therapeutics' stock price target for 2024?

3 brokers have issued 12 month price targets for Achilles Therapeutics' stock. Their ACHL share price targets range from $2.00 to $6.00. On average, they anticipate the company's share price to reach $4.00 in the next year. This suggests a possible upside of 400.0% from the stock's current price. View analysts price targets for ACHL or view top-rated stocks among Wall Street analysts .

How have ACHL shares performed in 2024?

Achilles Therapeutics' stock was trading at $0.8890 at the beginning of 2024. Since then, ACHL shares have decreased by 10.0% and is now trading at $0.80. View the best growth stocks for 2024 here .

Are investors shorting Achilles Therapeutics?

Achilles Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 74,800 shares, an increase of 8.6% from the March 15th total of 68,900 shares. Based on an average daily trading volume, of 768,800 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.2% of the company's shares are sold short. View Achilles Therapeutics' Short Interest .

When is Achilles Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our ACHL earnings forecast .

How were Achilles Therapeutics' earnings last quarter?

Achilles Therapeutics plc (NASDAQ:ACHL) posted its quarterly earnings data on Friday, August, 4th. The company reported ($0.42) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by $0.02.

When did Achilles Therapeutics IPO?

Achilles Therapeutics (ACHL) raised $176 million in an initial public offering on Wednesday, March 31st 2021. The company issued 9,800,000 shares at $17.00-$19.00 per share. JPMorgan, BofA Securities, Piper Sandler, Chardan, Oppenheimer & Co. and Kempen & Co. served as the underwriters for the IPO.

How do I buy shares of Achilles Therapeutics?

Shares of ACHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ACHL

Achilles Therapeutics (ACHL) Stock Price, News & Analysis

→ Explore the Future: Unlock the Top 3 AI Stocks for 2024 Report (From Darwin) (Ad)

Free ACHL Stock Alerts

$0.80

+0.01 (+0.63%)

(As of 12:16 PM ET)

Compare

Today's Range: $0.80
▼
$0.83
50-Day Range: $0.80
▼
$1.57
52-Week Range: $0.74
▼
$1.76

Volume: 76,898 shs
Average Volume: 685,787 shs
Market Capitalization: $32.10 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.00

Get Achilles Therapeutics alerts:

Achilles Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 400.0% Upside
$4.00 Price Target
Short Interest: Healthy
0.19% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.42
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.34) to ($1.33) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.89 out of 5 stars

Medical Sector

654th out of 918 stocks

Biological Products, Except Diagnostic Industry

112th out of 155 stocks

3.0

Analyst's Opinion

Consensus Rating
Achilles Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 1 hold rating, and 1 sell rating.
Amount of Analyst Coverage
Achilles Therapeutics has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.19% of the float of Achilles Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Achilles Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Achilles Therapeutics has recently increased by 8.56%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Achilles Therapeutics does not currently pay a dividend.
Dividend Growth
Achilles Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ACHL.

2.5

News and Social Media Coverage

News Sentiment
Achilles Therapeutics has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Achilles Therapeutics this week, compared to 0 articles on an average week.
Search Interest
Only 1 people have searched for ACHL on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.
MarketBeat Follows
4 people have added Achilles Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Achilles Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.38% of the stock of Achilles Therapeutics is held by insiders.
Percentage Held by Institutions
56.38% of the stock of Achilles Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Achilles Therapeutics are expected to grow in the coming year, from ($1.34) to ($1.33) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Achilles Therapeutics is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Achilles Therapeutics is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Achilles Therapeutics has a P/B Ratio of 0.23. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Darwin

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)

Click here to download your report

About Achilles Therapeutics Stock (NASDAQ:ACHL)

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.

ACHL Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ACHL Stock News Headlines

April 17, 2024 | msn.com

Achilles Therapeutics plc - Depositary Receipt () (ACHL) Price Target Decreased by 56.41% to 2.89

April 16, 2024 | americanbankingnews.com

Achilles Therapeutics plc (NASDAQ:ACHL) Sees Large Growth in Short Interest

April 19, 2024 | TradingTips (Ad)

3 Sub-$10 Stocks to Buy for 2024

Often, investors will overlook stocks just because they're cheap. It's a common thought that a cheap price tag means that something must be wrong with the company. But this couldn't be further from the case in many instances.

April 5, 2024 | msn.com

Piper downgrades Achilles to neutral, cites latest data

April 4, 2024 | markets.businessinsider.com

ACHL Stock Earnings: Achilles Therapeutics Misses EPS for Q4 2023

April 4, 2024 | finanznachrichten.de

Achilles Therapeutics PLC: Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights

April 4, 2024 | globenewswire.com

Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights

April 4, 2024 | globenewswire.com

Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning

April 19, 2024 | TradingTips (Ad)

3 Sub-$10 Stocks to Buy for 2024

March 7, 2024 | finance.yahoo.com

Will Achilles Therapeutics (NASDAQ:ACHL) Spend Its Cash Wisely?

February 22, 2024 | wsj.com

Achilles Therapeutics PLC ADR

February 22, 2024 | benzinga.com

Achilles Therapeutics Stock (NASDAQ:ACHL), Short Interest Report

February 9, 2024 | investing.com

Achilles Therapeutics PLC ADR (ACHL)

February 5, 2024 | finance.yahoo.com

Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference

December 22, 2023 | benzinga.com

Achilles Therapeutics Stock (NASDAQ:ACHL) Dividends: History, Yield and Dates

December 20, 2023 | seekingalpha.com

ACHL Achilles Therapeutics plc

December 18, 2023 | finance.yahoo.com

Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction

November 22, 2023 | foxnews.com

Steelers lose Kwon Alexander for season with torn Achilles: reports

November 14, 2023 | msn.com

Achilles Therapeutics GAAP EPS of -$0.42 misses by $0.02

October 29, 2023 | foxnews.com

As Aaron Rodgers rehabs from torn Achilles, doctor offers insight into recovery

September 23, 2023 | finanznachrichten.de

Achilles Therapeutics PLC: Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

September 22, 2023 | uk.style.yahoo.com

Are Medical Stocks Lagging Achilles Therapeutics (ACHL) This Year?

September 21, 2023 | usatoday.com

Aaron Rodgers says he's starting 'road to recovery' after Achilles surgery went 'great'

September 17, 2023 | usatoday.com

Jets QB Aaron Rodgers to miss rest of NFL season with torn Achilles

September 14, 2023 | cbsnews.com

Aaron Rodgers' Achilles injury is "not good," Jets head coach says, as star quarterback is set to get MRI

September 14, 2023 | dailymail.co.uk

Aaron Rodgers said he was 'manifesting' a Super Bowl run for the Jets in interview with John McEnroe that aired just MINUTES before he suffered season-ending Achilles injury

September 6, 2023 | finance.yahoo.com

Is KalVista Pharmaceuticals (KALV) Stock Outpacing Its Medical Peers This Year?

See More Headlines

Receive ACHL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Achilles Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/04/2023
Today: 4/19/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:ACHL
CUSIP: N/A
CIK: 1830749
Web: www.achillestx.com
Phone: 44-0-20-8154-4600
Fax: N/A
Employees: 204
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $4.00
High Stock Price Target: $6.00
Low Stock Price Target: $2.00
Potential Upside/Downside: +400.0%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.74)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-69,670,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -42.55%
Return on Assets: -37.54%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.57
Quick Ratio: 8.57

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.49 per share
Price / Book: 0.23

Miscellaneous

Outstanding Shares: 39,880,000
Free Float: 37,734,000
Market Cap: $31.90 million
Optionable: Not Optionable
Beta: 1.09

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Dr. Iraj Ali Ph.D. (Age 49)
CEO & Director
Comp: $1.7M
Dr. Karl Stuart Peggs M.D. (Age 57)
Founder & Chief Medical Officer
Dr. Sergio A. Quezada Ph.D. (Age 49)
Founder & Chief Scientific Officer
Mr. Robert Coutts (Age 40)
Chief Financial Officer
Dr. Mark William Lowdell BSc (Age 61)
FRCPath, MICR, MSc, Ph.D., Founder
Dr. Charles Swanton FMEDSCI (Age 51)
M.D., Ph.D., Founder
Mr. Lee M. Stern
Vice President of Investor Relations & External Communications
Mr. Daniel Carey Cazel Hood
General Counsel & Company Secretary
Julia Wilson
Head of Communications
Mr. Tariq Ahmed
Executive Vice President of People

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ACHL Stock Analysis - Frequently Asked Questions

Should I buy or sell Achilles Therapeutics stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Achilles Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ACHL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACHL, but not buy additional shares or sell existing shares.
View ACHL analyst ratings or view top-rated stocks.
What is Achilles Therapeutics' stock price target for 2024?: 3 brokers have issued 12 month price targets for Achilles Therapeutics' stock. Their ACHL share price targets range from $2.00 to $6.00. On average, they anticipate the company's share price to reach $4.00 in the next year. This suggests a possible upside of 400.0% from the stock's current price.
View analysts price targets for ACHL or view top-rated stocks among Wall Street analysts.
How have ACHL shares performed in 2024?: Achilles Therapeutics' stock was trading at $0.8890 at the beginning of 2024. Since then, ACHL shares have decreased by 10.0% and is now trading at $0.80.
View the best growth stocks for 2024 here.
Are investors shorting Achilles Therapeutics?: Achilles Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 74,800 shares, an increase of 8.6% from the March 15th total of 68,900 shares. Based on an average daily trading volume, of 768,800 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.2% of the company's shares are sold short.
View Achilles Therapeutics' Short Interest.

When is Achilles Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our ACHL earnings forecast.
How were Achilles Therapeutics' earnings last quarter?: Achilles Therapeutics plc (NASDAQ:ACHL) posted its quarterly earnings data on Friday, August, 4th. The company reported ($0.42) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by $0.02.
When did Achilles Therapeutics IPO?: Achilles Therapeutics (ACHL) raised $176 million in an initial public offering on Wednesday, March 31st 2021. The company issued 9,800,000 shares at $17.00-$19.00 per share. JPMorgan, BofA Securities, Piper Sandler, Chardan, Oppenheimer & Co. and Kempen & Co. served as the underwriters for the IPO.
How do I buy shares of Achilles Therapeutics?: Shares of ACHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ACHL) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial